SAN FRANCISCO -- Patients who discontinue the osteoporosis drug denosumab (Prolia) have an increased fracture risk that major clinical trials did not reflect, recent case reports documented. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results